白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2010年
10期
604-606
,共3页
许晓强%张巧花%侯淑玲%白林海
許曉彊%張巧花%侯淑玲%白林海
허효강%장교화%후숙령%백림해
淋巴瘤,大细胞,弥漫型%细胞因子类%药物疗法%抗药性,肿瘤
淋巴瘤,大細胞,瀰漫型%細胞因子類%藥物療法%抗藥性,腫瘤
림파류,대세포,미만형%세포인자류%약물요법%항약성,종류
Lymphoma,large-cell,diffuse%Cytokines%Drug therapy%Drug resistance,neoplasms
目的 探讨弥漫大B细胞淋巴瘤(DLBCL)患者血清细胞因子白细胞介素(IL)-2、IL-6、IL-8、IL-10、肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)表达水平与化疗耐药之间的相关性.方法 30例DLBCL化疗耐药患者为化疗耐药组,30例DLBCL化疗敏感患者为化疗敏感组,20名健康人作为健康对照组,ELISA法测定两组DLBCL患者治疗前、中、后及对照组血清中IL-2、IL-6、IL-8、IL-10、TNF-α、IFN-γ水平.结果 化疗耐药组患者血清中的IL-6、IL-10治疗前表达水平明显高于化疗敏感组患者治疗前和对照组表达水平(P值均＜0.05),治疗缓解后明显低于治疗前(P=0.02、P=0.015).DLBCL复发耐药时,患者血清中的IL-6、IL-10又高于缓解时水平(P=0.004、P＜0.001).化疗耐药组Ⅲ～Ⅳ期患者治疗前IL-6水平明显高于Ⅰ～Ⅱ期患者(P＜0.05).其他细胞因子IL-2、IL-8、TNF-α、IFN-γ水平在化疗耐药组、化疗敏感组、对照组之间差异无统计学意义(P＞0.05).结论 DLBCL患者血清中的IL-6、IL-10表达水平的高低与DLBCL化疗疗效密切相关,可能与DLBCL细胞耐药有关.
目的 探討瀰漫大B細胞淋巴瘤(DLBCL)患者血清細胞因子白細胞介素(IL)-2、IL-6、IL-8、IL-10、腫瘤壞死因子-α(TNF-α)、榦擾素-γ(IFN-γ)錶達水平與化療耐藥之間的相關性.方法 30例DLBCL化療耐藥患者為化療耐藥組,30例DLBCL化療敏感患者為化療敏感組,20名健康人作為健康對照組,ELISA法測定兩組DLBCL患者治療前、中、後及對照組血清中IL-2、IL-6、IL-8、IL-10、TNF-α、IFN-γ水平.結果 化療耐藥組患者血清中的IL-6、IL-10治療前錶達水平明顯高于化療敏感組患者治療前和對照組錶達水平(P值均＜0.05),治療緩解後明顯低于治療前(P=0.02、P=0.015).DLBCL複髮耐藥時,患者血清中的IL-6、IL-10又高于緩解時水平(P=0.004、P＜0.001).化療耐藥組Ⅲ～Ⅳ期患者治療前IL-6水平明顯高于Ⅰ～Ⅱ期患者(P＜0.05).其他細胞因子IL-2、IL-8、TNF-α、IFN-γ水平在化療耐藥組、化療敏感組、對照組之間差異無統計學意義(P＞0.05).結論 DLBCL患者血清中的IL-6、IL-10錶達水平的高低與DLBCL化療療效密切相關,可能與DLBCL細胞耐藥有關.
목적 탐토미만대B세포림파류(DLBCL)환자혈청세포인자백세포개소(IL)-2、IL-6、IL-8、IL-10、종류배사인자-α(TNF-α)、간우소-γ(IFN-γ)표체수평여화료내약지간적상관성.방법 30례DLBCL화료내약환자위화료내약조,30례DLBCL화료민감환자위화료민감조,20명건강인작위건강대조조,ELISA법측정량조DLBCL환자치료전、중、후급대조조혈청중IL-2、IL-6、IL-8、IL-10、TNF-α、IFN-γ수평.결과 화료내약조환자혈청중적IL-6、IL-10치료전표체수평명현고우화료민감조환자치료전화대조조표체수평(P치균＜0.05),치료완해후명현저우치료전(P=0.02、P=0.015).DLBCL복발내약시,환자혈청중적IL-6、IL-10우고우완해시수평(P=0.004、P＜0.001).화료내약조Ⅲ～Ⅳ기환자치료전IL-6수평명현고우Ⅰ～Ⅱ기환자(P＜0.05).기타세포인자IL-2、IL-8、TNF-α、IFN-γ수평재화료내약조、화료민감조、대조조지간차이무통계학의의(P＞0.05).결론 DLBCL환자혈청중적IL-6、IL-10표체수평적고저여DLBCL화료료효밀절상관,가능여DLBCL세포내약유관.
Objective To investigate the correlation between expression levels of serum cytokines IL-2,IL-6, IL-8, IL-10, TNF-α and IFN-γ in patients with diffuse large B-cell lymphoma(DLBCL) and chemotherapy resistance. Methods 30 cases of DLBCL patients with chemotherapy resistant, 30 cases of DLBCL patients with chemotherapy sensitive and 20 cases of healthy individuals as normal control group were enrolled. The levels of serum cytokines IL-2, IL-6, IL-8, IL-10, TNF-α and IFN-γbefore, during and after treatment in both DLBCL groups and normal control group were detected by ELISA assay. Results The expression level of serum IL-6 and IL-10 before treatment in DLBCL patients with chemotherapy resistance was significantly higher than that in DLBCL patients with chemotherapy sensitive and normal control group (P ＜ 0.05), however,that after treatment in DLBCL patients with chemotherapy resistance was significantly lower than that before treatment (P = 0.02, P = 0.015). The level of serum IL-6 and IL-10 in patients with DLBCL recurrence into drug resistance was higher than that during of remission (P = 0.004, P ＜0.001). Before treatment, the expression level of serum IL-6 in patients with Ⅲ-Ⅳ stage in chemotherapy resistant group was significantly higher than that in ones with Ⅰ - Ⅱ stage(P ＜0.05). Levels of IL-2, IL-8, TNF-α and IFN-γin chemotherapy resistant group, chemotherapy sensitive group and the normal control group were no differences (P ＞0.05).Conclusion The expression levels of the serum IL-6 and IL-10 were closely correlated with the chemotherapy efficacy of DLBCL, they may be involved in drug resistance of DLBCL.
